Document Detail

Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
MedLine Citation:
PMID:  20544514     Owner:  NLM     Status:  MEDLINE    
We have retrospectively investigated the effects of three strong statins, atorvastatin, pitavastatin, and rosuvastatin, on serum uric acid (SUA) levels. SUA levels after a few months of statin treatment were compared with those before treatment in 150 outpatients with dyslipidemia. In the atorvastatin (n = 62) and rosuvastatin (n = 45) groups, the SUA levels were reduced by 6.5% (p < 0.0001) and 3.6% (p = 0.03) respectively, but in the pitavastatin group (n = 43), the SUA level increased by 3.7% (p = 0.38). Because uric acid is considered a risk factor for cardiovascular disorders, atorvastatin or rosuvastatin treatment may be recommended when statins are used in patients at high risk for cardiovascular disorders complicated with hyperuricemia.
N Ogata; S Fujimori; Y Oka; K Kaneko
Related Documents :
6618154 - Chemical structures of angiotensins formed by incubating plasma with the kidney and the...
913024 - Uricosuric effects of niridazole.
15384794 - Effect of icodextrin on transperitoneal uric acid and albumin transport in vitro.
10425354 - Electrostatic charging during a melt agglomeration process.
9573164 - Suppressor scanning at positions 177 and 236 in the escherichia coli lactose/h+ cotrans...
6967504 - The enterohepatic physiology of 24,25-dihydroxyvitamin d3.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Nucleosides, nucleotides & nucleic acids     Volume:  29     ISSN:  1532-2335     ISO Abbreviation:  Nucleosides Nucleotides Nucleic Acids     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-14     Completed Date:  2010-09-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100892832     Medline TA:  Nucleosides Nucleotides Nucleic Acids     Country:  England    
Other Details:
Languages:  eng     Pagination:  321-4     Citation Subset:  IM    
Department of Internal Medicine, Teikyo University Scool of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / therapeutic use*
Cholesterol, LDL / blood
Dyslipidemias / blood*,  drug therapy*
Fluorobenzenes / therapeutic use*
Heptanoic Acids / therapeutic use*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Pyrimidines / therapeutic use*
Pyrroles / therapeutic use*
Quinolines / therapeutic use*
Sulfonamides / therapeutic use*
Uric Acid / blood*
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Fluorobenzenes; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Pyrroles; 0/Quinolines; 0/Sulfonamides; 110862-48-1/atorvastatin; 147526-32-7/NK 104; 287714-41-4/rosuvastatin; 69-93-2/Uric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Establishment and Analysis of SLC22A12 (URAT1) Knockout Mouse.
Next Document:  Metabolic syndrome characteristics in gout patients.